Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B - Asset Resilience Ratio
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has an Asset Resilience Ratio of 1.33% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Shanghai Shenqi Pharmaceutical Investmen to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 900904 asset base.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 900904 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.00 Million | 1.33% |
| Total Liquid Assets | $40.00 Million | 1.33% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B maintains only 1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Industry Peers by Asset Resilience Ratio
Compare Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Annual Asset Resilience Ratio for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.67% | $20.87 Million | $3.12 Billion | +0.03pp |
| 2023-12-31 | 0.64% | $20.90 Million | $3.28 Billion | -- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more